Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company using biomarkers and augmented intelligence to help physicians identify the location of chronic low back pain, has published a shareholder letter from CEO Brent Ness. The letter details the company's recent momentum and value-creating priorities for 2026, including reimbursement initiatives, clinical trial progress, and a strong financial position.
According to the letter, Aclarion is pursuing reimbursement coverage from one or more regional insurance providers in the United States, which the company views as an important step toward broader payer adoption. This follows progress in the United Kingdom, where the company has been advancing reimbursement initiatives. The letter also highlights the ongoing CLARITY clinical trial, with an initial data readout expected in the fourth quarter of 2026. The trial is designed to further validate the Nociscan platform's ability to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
Ness emphasized disciplined execution against key catalysts that could expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of the business. The company reported a strong balance sheet with cash runway into 2028, supporting continued commercial engagement with physicians and imaging centers.
Aclarion's Nociscan platform uses magnetic resonance spectroscopy (MRS) data from an MRI machine, processed through proprietary signal processing techniques and augmented intelligence algorithms to quantify chemical biomarkers associated with disc pain. The platform is designed to provide critical insights into the location of a patient's low back pain, helping optimize treatment strategies.
The full CEO Shareholder Letter is available on the company's website at www.aclarion.com. For more news from Aclarion, visit the company's latest news page at https://tinyurl.com/aconnewsroom.
